Skip to main content
PMC home page
Cancer Science logoLink to Cancer Science
. 2005 Aug 19;94(1):99–102. doi: 10.1111/j.1349-7006.2003.tb01359.x

Lack of correlation between expression of human mammaglobin mRNA in peripheral blood and known prognostic factors for breast cancer patients

Yung‐Chang Lin 1,✉, Shin‐Chie Chen 2, Swei Hsueh 3, Yung‐Feng Lo 2, Ye‐Hwei Chow‐Wu 4, I‐Chin Liaw 1, An‐Joy Cheng 5
PMCID: PMC11160282  PMID: 12708482

Abstract

Human mammaglobin (hMAM) mRNA is considered to be a promising candidate for a sensitive molecular marker for breast cancer. In this study, we attempted to relate the presence of hMAM mRNA in the peripheral blood with certain established clinico‐pathological features of breast cancer in order to validate its clinical utility. A total of 139 subjects including 79 with localized cancer, 33 with metastatic disease, and a control group of 27 individuals were studied. hMAM mRNA expression was assessed by reverse transcriptase polymerase chain reaction on cells from peripheral blood. The expression of hMAM mRNA was found in 0 of the 27 control subjects, 1 of the 8 stage 0 (12.5%) patients, 4 of the 16 stage I (25%) patients, 13 of the 40 stage II (32.5%) patients, 5 of the 15 stage III (33.3%) patients, and 18 of the 33 (54%) cases of metastatic disease. There was a statistically significant (P=0.045) difference in frequency between patients with localized disease (29%) and those with metastatic disease. Although trends of increasing frequency of hMAM mRNA expression existed in patients with unfavorable prognostic factors, including primary tumor size, T stage, N stage, overall stage, presence of angiolymphatic permeation, negative estrogen receptor, high S‐phase fraction (>7%), and aneuploid DNA index, none of the differences was significant. In conclusion, the clinical utility of hMAM mRNA may not be in screening or staging of breast cancer, but in following patients after surgery to detect recurrence. Further evaluation of hMAM mRNA in combination with other molecular markers to follow post‐operative breast cancer patient is warranted. (Cancer Sci 2003; 94: 99–102)

References

  • 1. Gianni L, Valagussa P, Zambetti M, Moliterni A, Carpi G, Banodonna G. Adjuvant and neoadjuvant treatment of breast cancer. Semin Oncol 2001; 28: 13–29. [DOI] [PubMed] [Google Scholar]
  • 2. Sloane JP, Ormerod MG, Neville AM. Potential pathological application of immunocytochemical methods to the detection of micrometastases. Cancer Res 1980; 40: 3079–82. [PubMed] [Google Scholar]
  • 3. Cote RJ, Rosen PP, Lesser ML, Old LJ, Osborne MP. Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. J Clin Oncol 1991; 9: 1749–56. [DOI] [PubMed] [Google Scholar]
  • 4. Harbeck N, Untch M, Pache L, Eiermann W. Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: results of a three‐year median follow‐up. Br J Cancer 1994; 69: 566–71. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5. Ghossenin RA, Juan R. Polymerase chain reaction in the detection of micrometastases and circulating tumor cells. Cancer 1996; 78: 10–6. [DOI] [PubMed] [Google Scholar]
  • 6. Salvadori B, Squicciarini P, Rovini D, Orefice S, Andreola S, Rilke F, Barletta L, Menard S, Colnaghi MI. Use of monoclonal antibody MBrl to detect micrometastases in bone marrow specimen of breast cancer patients. Eur J Cancer 1990; 26: 865–7. [DOI] [PubMed] [Google Scholar]
  • 7. Neumaier M, Gerhard M, Wagner C. Diagnosis of micrometastases by the amplification of tissue‐specific gene. Gene 1995; 159: 43–7. [DOI] [PubMed] [Google Scholar]
  • 8. Mori M, Mimori K, Ueo H, Tsuji K, Shiraishi T, Barnard GF, Sugimachi K, Akiyoshi T. Clinical significance of molecular detection of carcinoma cells in lymph nodes and peripheral blood by reverse transcription‐polymerase chain reaction in patients with gastrointestinal or breast cancer. J Clin Oncol 1998; 16: 128–32. [DOI] [PubMed] [Google Scholar]
  • 9. Schoenfeld A, Kriger KH, Gomm J, Sinnett HD, Gazet JC, Sacks N, Bender HG, Luqmani Y, Coombes RC. The detection of micrometastases in the peripheral blood and bone marrow of patients with breast cancer using immunohistochemistry and reverse transcriptase polymerase chain reaction for keratin 19. Eur J Cancer 1997; 33: 854–61. [DOI] [PubMed] [Google Scholar]
  • 10. Fields KK, Elfenbein GJ, Trudeau WL, Perkins JB, Janssen WE, Moscinski LC. Clinical significance of bone marrow metastases as detected using the polymerase chain reaction in patients with breast cancer undergoing high‐dose chemotherapy and autologous bone marrow transplantation. J Clin Oncol 1996; 14: 1868–76. [DOI] [PubMed] [Google Scholar]
  • 11. Datta YH, Adams FT, Drobyski WR, Ethier SP, Terry VH, Roth MS. Sensitive detection of occult breast cancer by the reverse transcriptase polymerase chain reaction. J Clin Oncol 1994; 12: 475–82. [DOI] [PubMed] [Google Scholar]
  • 12. Ethier SP, Terry VH, Roth MS, Trudeau WL, Field KK. High sensitivity detection of minimal residual breast carcinoma using the polymerase chain reaction and primers for cytokeratin 19. Diagn Mol Pathol 1996; 5: 173–80. [DOI] [PubMed] [Google Scholar]
  • 13. Kruger W, Krzizanowski C, Holweg M, Stockschlader M, Kroger N, Jung R, Mross K, Jonat W, Zander AR. Reverse transcriptase/polymerase chain reaction detection of cytokeratin 19 mRNA in bone marrow and blood of breast cancer patients. J Cancer Res Clin Oncol 1996; 122: 679–86. [DOI] [PubMed] [Google Scholar]
  • 14. Burchill SA, Bradbury MF, Pittman K, Southgate J, Smith B, Selby P. Detection of epithelial cancer cells in peripheral blood by reverse transcriptase‐polymerase chain reaction. Br J Cancer 1995; 71: 278–81. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. Mori M, Mimori K, Ueo H, Karimine N, Barnard GF, Sugimachi K, Akiyoshi T. Molecular detection of circulating solid carcinoma cells in the peripheral blood: the concept of early systemic disease. Int J Cancer 1996; 68: 739–43. [DOI] [PubMed] [Google Scholar]
  • 16. Gerhard M, Juhl H, Kalthoff H, Schreiber HW, Wagener C, Neumaier M. Specific detection of carcinoembryonic antigen‐expression tumor cells in bone marrow aspirate by polymerase chain reaction. J Clin Oncol 1994; 12: 725–9. [DOI] [PubMed] [Google Scholar]
  • 17. Mapara MY, Korner IJ, Hilderbrandt M, Bargou R, Krahl D, Reichardt P, Dorken B. Monitoring of tumor cell purging after highly efficient immuno‐magnetic selection of CD34 cells from leukapheresis products in breast cancer patients: comparison of immunohistochemical tumor cell staining and reverse transcriptase‐polymerase chain reaction. Blood 1997; 89: 337–44. [PubMed] [Google Scholar]
  • 18. Raj GV, Moreno LG, Gomella LG. Utilization of polymerase chain reaction technology in the detection of solid tumor. Cancer 1998; 82: 1419–42. [DOI] [PubMed] [Google Scholar]
  • 19. Hu XI, Chow WC. Detection of circulating breast cancer cells with multiple‐marker RT‐PCR assay. Anticancer Res 2001; 21: 421–4. [PubMed] [Google Scholar]
  • 20. Chelly J, Concordet JP, Kaplan JC, Kahn A. Illegitimate transcription: transcription of any gene in any cell type. Proc Natl Acad Sci USA 1989; 86: 2617–21. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. Bastick PJ, Chatterjee S, Chi DD, Huynh KT, Giuliano AE, Cote R, Hoon DS. Limitation of specific reverse‐transcriptase polymerase chain reaction markers in the detection of metastases in the lymph nodes and blood of breast cancer patients. J Clin Oncol 1998; 16: 2632–40. [DOI] [PubMed] [Google Scholar]
  • 22. Watson MA, Fleming TP. Mammaglobin, a mammary‐specific member of the uteroglobin gene family, is overexpressed in human breast cancer. Cancer Res 1996; 56: 860–5. [PubMed] [Google Scholar]
  • 23. Zach O, Kasparu H, Krieger O, Hehenwarter W, Girschikofsky M, Lutz D. Detection of circulating mammary carcinoma cells in the peripheral blood of breast cancer patients via a nested reverse transcriptase polymerase chain reaction assay for mammaglobin mRNA. J Clin Oncol 1999; 17: 2015–9. [DOI] [PubMed] [Google Scholar]
  • 24. Grunewald K, Haun M, Urbanek M, Figel M, Muller‐Holzner E, Gunsilius E, Dunser M, Marth C, Castl G. Mammaglobin gene expression: a superior marker of breast cancer cells in peripheral blood in comparison to epidermal‐growth‐factor receptor and cytokeratin 19. Lab Invest 2000; 80: 1071–7. [DOI] [PubMed] [Google Scholar]
  • 25. Corradini P, Voena C, Astolfi M, Pilotti S, Arrigoni G, Bregni M, Pileri A, Gianni AM. Mapsin and mammaglobin genes are specific markers for RT‐PCR detection of minimal residual disease in patients with breast cancer. Ann Oncol 2001; 12: 1693–8. [DOI] [PubMed] [Google Scholar]
  • 26. Watson MA, Dintzis S, Darrow CM, Voss LE, DiPersio J, Jensen R, Fleming TP. Mammaglobin expression in primary, metastatic and occult breast cancer. Cancer Res 1999; 59: 3028–31. [PubMed] [Google Scholar]
  • 27. Leygue E, Snell L, Dotzlaw H, Hole K, Troup S, Hiller‐Hitchcock T, Murphy LC, Watson PH. Mammaglobin, a potential marker of breast cancer nodal metastasis. J Pathol 1999; 189: 28–33. [DOI] [PubMed] [Google Scholar]
  • 28. Suchy B, Austrup F, Driesel G., Edre C, Kusiak I, Uciechowski P, Grill H‐J, Giesing M. Detection of mammaglobin expression cells in blood of breast cancer patients. Cancer Lett 2000; 158: 171–8. [DOI] [PubMed] [Google Scholar]
  • 29. Winner EP, Morrow M, Osborne CK, Harris JA. Malignant tumors of the breast. In: Devitta VT, Hellman S, Rosenberg SA, editors. Cancer, principles and practice of oncology. 6th ed. Philadelphia : Lippincott Williams & Wilkins; 2001. p. 1651–717. [Google Scholar]
  • 30. Funke I, Schraut W. Meta‐analysis of studies on bone marrow micrometastases: an independent prognostic impact remains to be substantiated. J Clin Oncol 1998; 16: 557–66. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Science are provided here courtesy of Wiley

RESOURCES